Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Vioxx Label Balances CV Risk With GI Safety: Can Merck Reverse Damage?

Apr 15 2002

• By The Pink Sheet

Related Content

COX-2 Class Labeling From Vioxx/Celebrex Data Proposed By FDA Consultant

Feb 19 2001

Merck COX-2 Cardiovascular Safety Studies Will Enroll 30,000 Subjects

Dec 17 2001

FDA Anti-Inflammatory Division Director Will Be Celebrex Investigator Simon

Sep 03 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window